Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project
30 Agosto 2017 - 12:07PM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”)
announces that the Australian Research Council (ARC) has awarded
Prima and research partner Monash University a A$360,000 grant
under its Linkage Project scheme to help fund a research project
into the role of LAG-3 in immune responses.
In collaboration with Prima, Monash University’s Biomedicine
Discovery Institute (BDI) Chief Investigator, Professor Jamie
Rossjohn will conduct the study titled ‘Investigating the structure
of a T cell immune checkpoint molecule’. It will assess T cell
receptors and their role in the immune system and provide insights
into the LAG-3 function and how it controls T cell signalling. The
study could ultimately lead to the development of new innovative T
cell immunomodulatory agents. ARC Laureate Fellow and Head of the
Infection and Immunity Program at the Monash BDI, Professor Jamie
Rossjohn, said: “This funding shows huge support for
immunotherapeutics. Our proposal is innovative in combining
state-of-the-art technology that will be fully integrated with the
ground breaking work of Dr Triebel, the leading authority in LAG-3
biology. This will help us to further understand the way that LAG-3
controls T cell signalling, which is important for both cancer and
autoimmunity.”
Prima’s Chief Scientific and Medical Officer, Dr Frederic
Triebel, also welcomed the grant and said: “Working alongside one
of the leading international groups in structural immunology, we
are seeking to determine for the first time how LAG-3 binds with
MHC class II and how this interaction is disrupted by the blocking
antibodies presently tested as immune checkpoint inhibitors for
cancer patients in clinical trials.”
The study will be conducted over a three year period. Professor
Rossjohn will have overall oversight of the project and will be
responsible for resources management of the grant. As the leading
authority on LAG-3, Dr Triebel will provide his expertise and
facilitate access to relevant LAG-3 specific constructs, reagents,
mAb directed against LAG-3. Prima will also make a small additional
cash contribution towards the study and provide staff and
materials.
About the Monash Biomedicine Discovery
InstituteCommitted to making the discoveries that will
relieve the future burden of disease, the newly established Monash
Biomedicine Discovery Institute at Monash University brings
together more than 120 internationally-renowned research teams. The
research teams are supported by world-class technology and
infrastructure, and partner with industry, clinicians and
researchers internationally to enhance lives through discovery.
Professor Jamie Rossjohn FAA FLSW
FMedSci Professor Jamie Rossjohn is an Australian Research
Council Laureate Fellow at Monash Biomedicine Discovery Institute,
Monash University and Professor in Structural Immunology at Cardiff
University. Professor Rossjohn is recognized for his
contributions to understanding molecular bases of immunity.
Prima BioMed
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please contact:
U.S. Investors:
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
Grafico Azioni Immutep Limited (NASDAQ:PBMD)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Immutep Limited (NASDAQ:PBMD)
Storico
Da Giu 2023 a Giu 2024